Key result
Low height-indexed ASMM is linked to ~76% higher 2-year mortality and improves risk reclassification.
Why the study?
In heart failure, BMI fluctuations with congestion may weaken the interpretability of newly endorsed BMI-indexed appendicular skeletal muscle mass (ASMM). Direct comparative data on the prognostic utility of BMI-indexed versus conventional height-indexed ASMM in older patients with heart failure were limited.
Does height-indexed appendicular skeletal muscle mass improve prognostic risk stratification for 2-year all-cause mortality compared to BMI-indexed appendicular skeletal muscle mass in older patients hospitalized for heart failure?
Cohort (n=900)
Yes
Does height-indexed appendicular skeletal muscle mass improve prognostic risk stratification for 2-year all-cause mortality compared to BMI-indexed appendicular skeletal muscle mass in older patients hospitalized for heart failure?
In older patients hospitalized for heart failure, height-indexed appendicular skeletal muscle mass predicts 2-year all-cause mortality and improves risk reclassification, whereas the newly endorsed BMI-indexed definition does not.
Supports height-indexed ASMM for mortality risk stratification in older HF; challenges BMI-indexed sarcopenia criteria but leaves open clinical adoption.
Background The Asian Working Group for Sarcopenia 2025 consensus newly endorses appendicular skeletal muscle mass (ASMM) indexed to body mass index (BMI), in addition to conventional height indexing. In heart failure, BMI may fluctuate with congestion and decongestion, potentially weakening the clinical interpretability of BMI-indexed ASMM. However, direct comparative data on the prognostic utility of BMI-indexed versus height-indexed ASMM in older patients with heart failure remain limited. Purpose To compare the prognostic utility of BMI-indexed versus height-indexed ASMM in older patients hospitalized for heart failure. Methods This was a post-hoc analysis of the FRAGILE-HF study, a prospective, multicentre observational cohort of patients aged ≥65 years hospitalized for heart failure. Of 1,332 participants, 900 with bioelectrical impedance analysis data were included (median age 81 [IQR 74–86] years; 42.4% women). BMI-indexed ASMM (ASMM/BMI) and height-indexed ASMM (ASMM/height²) were calculated, and low muscle mass was defined using established sex-specific thresholds. Two logistic regression models were constructed for the primary outcome. Specifically, low versus high muscle mass, defined using BMI-indexed ASMM and height-indexed ASMM, was added to a baseline model comprising the MAGGIC risk score and log-transformed BNP. Prognostic performance across the three models was compared using the area under the receiver operating characteristic curve (ROC-AUC) and net reclassification improvement (NRI). The primary outcome was 2-year all-cause mortality. Results Low BMI-indexed ASMM and low height-indexed ASMM were present in 17.6% and 26.2% of patients, respectively. During 2-year follow-up, 160 deaths occurred (18.0%). Kaplan–Meier analysis demonstrated no difference in survival between low and high BMI-indexed ASMM (log-rank P=0.492); conversely, survival differed significantly between low and high height-indexed ASMM (log-rank P<0.001). In an adjusted Cox proportional hazards model, low BMI-indexed ASMM was not associated with 2-year mortality (HR 1.24 [95% CI 0.82–1.88], P=0.308), whereas low height-indexed ASMM was associated with a higher risk of death (HR 1.76 [95% CI 1.24–2.49], P=0.002). When comparing the model including height-indexed ASMM with the model including BMI-indexed ASMM, discrimination did not differ significantly (AUC 0.703 vs 0.686, P=0.155). Nonetheless, replacing BMI-indexed ASMM with height-indexed ASMM significantly improved risk reclassification (NRI 0.350 [95% CI 0.173–0.527], P<0.001). Conclusion In older patients hospitalised for heart failure, low height-indexed, but not BMI-indexed, ASMM was associated with higher 2-year post-discharge all-cause mortality and improved risk reclassification, supporting the use of height-indexed ASMM for prognostic risk stratification in this population.Figure_for_abstract
No takes yet. Share an insight, caveat, or question.
Nakade et al. (2026) conducted a cohort in Heart failure (n=900). Low height-indexed appendicular skeletal muscle mass (ASMM/height²) vs. Low BMI-indexed appendicular skeletal muscle mass (ASMM/BMI) and high muscle mass was evaluated on 2-year all-cause mortality (HR 1.76, 95% CI 1.24-2.49, p=0.002). Low height-indexed ASMM was associated with higher 2-year mortality (HR 1.76, 95% CI 1.24–2.49) and improved risk reclassification over BMI-indexed ASMM (NRI 0.350, P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: